All content in the ZeccoShare community is generated by its members and does not contain advice or recommendations on behalf of Zecco Holdings or Zecco Trading. More>>
Content Name: CommunityDisclaimerShortLeftNav
Preview Revision #:
Active Revision #:
Edit Content
Icecoldstocks.net's Blog

Icecoldstocks.com Tuesday Morning, September 11th Market Summary

Tuesday Morning, September 11th

   Dow Stock News

AIG´s (AIG) private banking unit is aiming to take 10 percent of Taiwan's wealth management market within five years, targeting residents who have made big money in China, a top executive said on Tuesday. - Reuters

HP (HPQ) and Crospon, a medical device developer based in Galway, Ireland, today announced they have entered a licensing agreement for a drug delivery platform that enables painless, controlled release of one or more drugs in a single patch applied to the skin.

McDonald's Corporation announced today that global comparable sales rose 8.1% in August. Systemwide sales for McDonald's restaurants worldwide increased 12.3% for the month (9.3% in constant currencies).

The Wall Street Journal writes that GM (GM) has made two proposals to the UAW. One would provide money for a healthcare fund run by the UAW. The other includes substantial job cuts.

   Ice Man Stocks

Breakouts the Ice Man may consider trading:

OIIM - 15.10
FDRY - 19.10
SMSC - 38.15
VIP - 25.70

Regular Trades the Ice Man may consider:

FMD - 35, 36.10
DNDN - 8.50
UNG - 37.40
SAFT - 35.50
SAI - 19 B = 19.59 G
CL - 67.05
CLX - 60.55
USU - 13.30
XTO - 57.55
JNJ - 62
RSYS - 11.50
BTJ - 38.50
AOB - 10.50

Depressed stocks the Ice Man may buy:

XOM - 80.70 G
BRG - 78.40 G
MGA - 81.10 G
MMM - 85.40 G
JCI - 104.60 G
CBE - 48.15 G
FCSX - 46.80 G
ANF - 72.80 G

Breakdown Shorts:

PAC - Breaking 48 = 45.30 G

Dollar Man Ideas:

CNOA - 2
NRMX - 3
CORT - 3.50
XTLB - 2
EEE - 4.60

Depressed Dollar:

CRDC - 7.50

   Media Commentators

Cramer's Comments:

Bullish: PEP, MHS, MO, NOC, MCD, PG, XOM, SLB, HPQ, DE, UTX, FWLT, COH

Louis Navellier:

Positive on NOK, QMAR, SHPGY and cautious on SINA;

   Ice Cold Commentators

Break Man Video Summary:

Break out buy (or short sell) watch list for short term gains September 11 includes: ARNA, FLO, DNDN, WBS, FXPE, ADBL, TGIC, WHQ.

Several candidates for break out or short sell  plays for at least short term gains by buying the break out (or selling the break down) on good volume and closing at least some on the  first day.


   CNBC Fast Money Review

1. ANOTHER BILLIONAIRE BUY-IN

  The headline: Bahama-Based Billionaire Joseph Lewis Takes 7% Stake In Bear Stearns
  Adami: likes Goldman Sachs and Morgan Stanley for their trading revenues.
  Najarian: recommends owning GS until earnings, then he says, “Get out!’
  Macke: doesn´t agree. He thinks GS stock has already rallied.
  Finerman: GS will “get creamed’ this quarter. She thinks their asset management has taken an enormous blow.

  2. CHIPS

  The headline: INTC Boosts Sales Outlook In Bid To Overshadow AMD Barcelona Chip Release
  Najarian: thinks Intel is a buy. He also likes AMD for global growth.
  Adami: tells the panel to trade AMD “at your own risk.’
  Macke: reveals that he´s long INTC as an investment.

  3. DEFENSE ON OFFENSE BEFORE CONFERENCE

  The headline: LMT, NOC Jumping Ahead Of Morgan Stanley Conference Tomorrow
  Adami: recommends buying both LMT and BA in the low $90´s. He also likes LLL.
  Najarian: look at HON as a way to play defense technology.

  4. Private Equity Party Over?

  Private equity giant KKR has reportedly made a concession to the banks financing its $26 billion buyout of FDC. Meanwhile, tougher lending terms amid the credit crunch sent BX to another low Monday. Is the party completely over for private equity?
  Najarian: believes BX is finally getting to a level where it´s a buy. He also feels the downside puts are cheap as protection.
  Adami: agrees.
  Finerman: the wheels are starting to turn again for private equity. She tells the panel if you´re short BX, it might be time to cover.
  Macke: doesn´t agree. He thinks private equity deals are over.

  5. TEXAS INSTRUMENTS

  The headline: Texas Instruments To Provide Mid-Quarter Update Tuesday After The Bell.
  Adami: anticipates TXN will narrow guidance Tuesday. On a related note, at these levels he likes this stock.
  Najarian: tells the panel TXN makes him nervous.

  6. POPS AND DROPS

  AAPL popped 4%: Adami says he can´t embrace Apple at this level.
  SNCR popped 6%: Najarian likes this stock.
  NMX popped 5%: Adami says speculation suggests NYX might soon buy NMX.
  DNDN popped 5%: Najarian says there´s speculation in the market that one of Dendreon´s drugs may get the fast track from the FDA.
  M dropped 2%: Macke thinks Macy´s is a sell.
  HOV dropped 5%: Macke says sell.
  LM dropped 4%: Adami believes the stock will go lower.

  7. YOUR FIRST MOVE FOR TUESDAY

  Macke: says sell the RTH – or if you´re an aggressive trader short it.
  Adami: recommends buying NMX on takeover talk.
  Finerman: prefers COP for the long haul.
  Najarian: likes DNDN on recent options activity.


   News and Events Digest

Breaking News

Countrywide Financial Corp. is putting together another multi-billion dollar bailout plan as the nation's largest home lender continues to struggle amid the global credit crunch and declines in the housing market, The Post has learned.

Sources familiar with Countrywide's plans said the lender continues to work with Goldman Sachs and law firm Wachtell Lipton Rosen & Katz to structure another strategic investment similar to the deal Bank of America struck last month. - NY Post

Nabi Biopharmaceuticals (NABI) said it's agreed to sell its Nabi Biologics strategic business unit to Biotest Pharmaceuticals for $185 million in cash. Nabi said the move puts the company on a "success outcome of our strategics alternatives process." Biotest said the deal will give it a share of the U.S. plasma protein market to complement its European plasma protein business. - MarketWatch

United State-based engine manufacturer Cummins Inc. (CMI) and Beijing-based truck Beiqi Foton Motor Co. have been given approval from the Chinese government to set up a joint-venture engine plant, according to reports Tuesday. Beiqi Foton said Tuesday the National Development and Reform Commission had approved the venture, Dow Jones Newswires reported, citing a company statement. The two companies will jointly invest 2.7 billion yuan ($358.89 million) in the venture, the report said. The venture will reportedly produce 2.8-liter and 3.8-liter Cummins light-duty diesel engines and target annual output of 400,000 units a year. Cummins and a wholly-owned unit in China will own 50% of the venture while Beijing Foton and a related unit will hold the remaning 50%, the report said. - MarketWatch

Roche Holding AG (RHHBY) said Tuesday it is suing Teva Pharmaceutical Industries Ltd. (TEVA) over a generic version of the Swiss drug company's Boniva, a treatment against osteoperosis. - MarketWatch

Capital Source (CSE) said it's completed $1.07 billion term financing of commercial real estate loans from its portfolio, which it will use to repay indebtedness from its credit facilities. The note may be increased to $1.5 billion over the next two months. After the transaaction, CapitalSource will have approximately $2.8 billion of undrawn commitments under its commercial loan credit facilities, and its balance of commercial loan term debt will be $4.4 billion. - MarketWatch

Senate Investigators have sent letters to at least 30 companies seeking details of past tax-cutting transactions. - WSJ

Sepracor, (SEPR) the Marlborough, Mass., drugmaker, and GlaxoSmithKline, (GSK) the U.K. health-care giant, agreed to commercialize eszopiclone worldwide except in the U.S., Canada, Mexico and Japan. Sepracor's eszopiclone treats insomnia. GlaxoSmithKline will market the drug under the name Lunivia. Sepracor will receive $20 million up front plus as much as $155 million in milestone and license fees, and royalties. Eszopiclone is currently under EMEA review for clearance in the European Union. The drug is marketed in the U.S. under the brand name Lunesta. - MarketWatch

ImClone Systems Inc. and Bristol-Myers Squibb Co. said Tuesday the drug Erbitux improved the survival rate of lung cancer patients in a late-stage study.

The drug, already approved to treat colon cancer and head and neck cancer, was given to patients with advanced non-small cell lung cancer in combination with chemotherapy treatment including vinorelbine and cisplatin. The study compared the combination to chemotherapy alone. - AP

Media Summary:

According to Reuters, oil prices jumped to $78 on news the pipelines in Mexico had been blown up.

Reuters reports that any possible extra OPEC crude supplies will be offset by planned maintenance on United Arab Emirates oilfields in late October and November, traders said on Tuesday.

The Wall Street Journal reports that hedge funds lost 1.3% in August, their worst performance in over a year.

The New York Times reports that a billionaire has bought a 7% stake in Bear Stearns (BSC).

The FT writes that a new report says that the push toward biofuels could drive food prices to levels to high for consumers to support.

Barron's writes that forecasts from Take-Two (TTWO) drove its share price higher.

Bloomberg reports that a large market for fake iPhones has emerged in Asia.

BusinessWeek reports that Apple (AAPL) may bid for the rights to a wireless spectrum auctioned by the Federal Communications Commission,

Silicon Alley Insider reports that the growth of YouTube's audience and its struggles with ad revenue could bring down reveue growth at Google (GOOG).

Economic Data:

8:30 Trade Balance

   Upgrades and Downgrades by Sector:

Biotech
 ALNY Alnylam Pharmaceuticals Cantor Fitzgerald Upgraded from Hold to Buy $20 to $32
 OMRI Omrix Biopharma Rodman & Renshaw Initiated at Mkt Outperform $46
 HALO Halozyme Therapeutics Morgan Joseph a Initiated at Sell $6

Broadcasting
 CHTR Charter Comm Lehman Brothers a Initiated at Underweight

Business Services
 CVG Convergys Wachovia Initiated at Outperform
 DM Dolan Media Piper Jaffray Initiated at Outperform
 G Genpact JP Morgan Initiated at Overweight

Chemicals
 AGU Agrium CIBC Wrld Mkts Price Target Raised Sector Outperform $49 to $56

Computer Hardware
 WDC Western Digital Bear Stearns Upgraded from Peer Perform to Outperform
 WDC Western Digital Caris & Company Price Target Raised Above Average $25 to $27
 SMOD Smart Modular Tech Needham & Co Downgraded from Buy to Hold
 SMOD Smart Modular Tech JMP Securities Downgraded from Strong Buy to Mkt Outper $20 to $12

Computer Services
 SNDA Shanda Interactive Citigroup Initiated at Buy $38

Computer Software
 SYMC Symantec Jefferies & Co Price Target Raised Buy $21 to $22
 LNUX SourceForge Stanford Research Initiated at Buy $4
 VDSI VASCO Data Security Friedman Billings Downgraded from Outperform to Mkt Perform $36
 VRNT Verint Systems CIBC Wrld Mkts Cut Price Target Sector Outperform $37 to $34
 VRNT Verint Systems Friedman Billings Cut Price Target Outperform $37 to $35

Finance Companies
 DLLR Dollar Financial Roth Capital Price Target Raised Buy $35 to $36

Gaming Operations
 SHFL Shuffle Master Roth Capital Cut Price Target Hold $18 to $15
 SHFL Shuffle Master Nollenberger Capital Cut Price Target Buy $29 to $23

Healthcare Facilities
 OCR Omnicare Matrix Research Downgraded from Buy to Hold

Hotels and Motels
 HOT TWPT Upgraded to Overweight

Industrial Equipment
 IRBT IRobot First Albany Price Target Raised Buy $23 to $26

Insurance
 KMA KMG America Friedman Billings Downgraded from Outperform to Mkt Perform $6 to $6.20

Mining Non-Ferr Metal
 RT Ruby Tuesday KeyBanc Capital Mkts Upgraded from Underweight to Hold

Pharmaceutical
 SCMP Sucampo Pharma CIBC Wrld Mkts Initiated at Sector Outperform $17

REITs
 TMA Thornburg Mortg UBS Upgraded from Neutral to Buy
 RAS RAIT Invtmt Trust RBC Capital Mkts Downgraded from Outperform to Underperform

Semiconductors
 LSI DBAB Upgraded to Buy

Telecommunications
 CMVT Comverse Tech Merriman Curhan Ford Upgraded from Neutral to Buy

Transportation
 EGLE Eagle Bulk Shipping Cantor Fitzgerald Price Target Raised Buy $31 to $33
 GNK Genco Shipping Trading Cantor Fitzgerald Cut Price Target Buy $71 to $69

Published Tuesday, September 11, 2007 2:11 PM by Icecoldstocks.net
Content Name: blogInnerAdPartBottom
Preview Revision #:
Active Revision #:
Edit Content

RSSRSS Syndication Feed

Or, add this feed directly to your favorite reader by clicking the button below. That way, you’ll never miss a post.

Add to NewsGator Add to Rojo Add to Pluck Add to my AOL Add to Netvibes Add to Pageflakes Add to my Yahoo Add to Bloglines Add to Google

Comments

No Comments
Anonymous comments are disabled

The above content is provided for educational and informational purposes only, does not constitute a recommendation to enter in any securities transactions or to engage in any of the investment strategies presented in such content, and does not represent the opinions of Zecco or its employees.


RSSRSS Syndication Feed

Or, add this feed directly to your favorite reader by clicking the button below. That way, you’ll never miss a post.

Add to NewsGator Add to Rojo Add to Pluck Add to my AOL Add to Netvibes Add to Pageflakes Add to my Yahoo Add to Bloglines Add to Google
Icecoldstocks.net's Blog
Content Name: BlogLayoutRight
Preview Revision #:
Active Revision #:
Edit Content


ZeccoShare is currently in Beta mode. In case you wish to provide feedback, please post it in the ZeccoShare Forum.

ZeccoShare provides a confined and secured environment. The information you share (e.g. profile, holdings, trades, performance) is only displayed to other Zecco members. Guest (i.e. not signed in) are not able to see any individual member information. Guests will only be able to see anonymous, aggregated community data.

Zecco members marked with a ‘Zecco Associate’ medal are employees of Zecco.com. They are not registered representatives of any broker/dealer, and are not registered with any national securities exchange. All information displayed and all posts made by these users are their personal information and opinion, and not the opinion or information of Zecco.com. Zecco.com is not a broker/dealer, has no access to material non-public information about publicly traded companies, and does not make any recommendations regarding the purchase or sale of any security.


All content in the ZeccoShare community is provided for educational and informational purposes only, does not constitute a recommendation to enter in any securities transactions or to engage in any of the investment strategies presented in such content, and does not represent the opinions of Zecco Holdings or its employees. Your use of the ZeccoShare Community is conditioned to your acceptance of all Disclosures and Terms of Service.
Close [X]
Content Name: CommunityDisclaimerLong
Preview Revision #:
Active Revision #:
Edit Content

Terms of Service - Privacy Policy


Zecco.com is a financial portal of Zecco Holdings, Inc., which also provides access to Zecco Trading, Inc.’s trading service. Zecco Holdings, inc. is not a securities broker/dealer. All securities and investments are offered to self-directed investors by Zecco Trading, Inc. Member FINRA /SIPC. More information is located on the disclosures page.

At Zecco Trading, you can make up to 10 free stock trades in any one month that you maintain a $2500 minimum account net equity. After that, you pay only $4.50 per stock trade. Options trades are $4.50 plus $.50 per contract. Only the first account of any account type is eligible for the Zecco Trading, Free Trading program. Any multiple accounts of the same type with the same registration are not eligible for the free trading program. Free Trading Program is only available through Zecco.com. $0 minimum to open cash and IRA accounts.

* Margin accounts require a $2,000 minimum balance for opening and trading on margin. Margin trading involves risks and is not suitable for all accounts.

Options involve risk and are not suitable for all investors. Please read Characteristics and Risks of Standardized Options.

Multiple leg options strategies involve additional risks and multiple commissions, and may result in complex tax treatments. Please read Spread Trading Disclosure.

Investors should consider the investment objectives, risks, and charges and expenses of a mutual fund or ETF carefully before investing. A mutual fund/ETF's prospectus contains this and other information, and should be read carefully before investing.

System response and access times may vary due to market conditions, system performance, and other factors.

The content of Zecco Holdings, Inc.'s and Zecco Trading, Inc.'s websites, including research, tools and securities symbols, is for educational and informational purposes and should not be intended as a recommendation or solicitation to engage in any particular securities transaction or investment strategy. You alone are responsible for evaluating the benefits and risks associated with the use of our services or products and to decide which securities and strategies better suit your financial situation and goals, risk profile, etc. The projections regarding the probability of investment outcomes are hypothetical and not guaranteed for accuracy or completeness. They do not reflect actual investment outcomes and are not guarantees of future results. Projections and tools' calculations do not take into consideration commissions, margin interest and other costs that will impact investment outcomes. All investments involve risk. Losses may exceed the principal invested. Past performance of a security, market, or financial product does not guarantee future results. Neither Zecco Holdings, Inc. nor Zecco Trading, Inc. offers any tax, legal or financial advice.

No consideration was paid for any testimonials displayed on this website. Your experience may vary, and the testimonials are no guarantee of future performance or success. Zecco Holdings, Inc., Zecco Trading, Inc.'s and their independent providers are not liable for any errors, incompleteness, or delays, or for any actions taken in reliance upon information contained herein. By accessing our websites, you agree not to redistribute the information found therein.

Market Data Copyright © QuoteMedia. Data delayed 15 to 20 minutes unless otherwise indicated. RT = Realtime, EOD = End Of Day, PD = Previous Day. Powered by QuoteMedia. Terms of Use.

© 2006-2008 Zecco Holdings, Inc. and Zecco Trading, Inc., Member FINRA /SIPC All rights reserved.